Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2020 Mar;153:104634. doi: 10.1016/j.phrs.2020.104634

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]

Katie Bechman 1,*, Mark Yates 1, James B Galloway 1
PMCID: PMC7181163  PMID: 32014340

In this article two typographical errors have been identified.

The sentence "At 12 w; significantly higher 15 mg, 30 mg v PBO ACR20 (65 %, 56 % v 48 %) in Table 3 is now corrected into "At 12 w; significantly higher 15 mg, 30 mg v PBO ACR20 (65 %, 56 % v 28%)”.

The study with Abrocitinib (PF-04965842) mentioned in Table 4 was a phase II not a phase III study as erroneously indicated.

The authors would like to apologise for any inconvenience caused.

RESOURCES